THE 5-SECOND TRICK FOR "3

All enrolled clients who obtained a minimum of one dose of zosuquidar or placebo for the duration of induction were being monitored for the event of adverse gatherings (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions have been connected to the duration of extended and significant myelosuppression as is expected